ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
47 announcements with these filters
Cohance Lifesciences scheduled a board meeting for August 5, 2026. The board will consider and approve the unaudited financial results for the quarter ended June 30, 2026.
Cohance Lifesciences provided a clarification to the NSE regarding their financial results filing, confirming submission of the required XBRL and non-machine readable format documents.
Cohance Lifesciences clarified that no pending information exists regarding the recent increase in trading volume. The company remains compliant with SEBI regulations.
Cohance Lifesciences shareholders approved all five resolutions via postal ballot. The resolutions include appointment of Chairman and CEO, remuneration, and ESOP plans.
Cohance Lifesciences Limited submitted its Annual Secretarial Compliance Report for the financial year 2026. The report notes a procedural delay in filing XBRL financial results with BSE.
Cohance Lifesciences issued a postal ballot notice for appointing Mr. Umang Vohra as Chairman and CEO. Shareholders will also vote on a new ESOP 2026 plan.
Cohance Lifesciences Ltd reported revenue from operations of ₹619.1 Cr (-26.3% YoY) and net profit of ₹8.3 Cr (-92.9% YoY) for Q4 FY26.
Management is navigating a transition phase with significant revenue and margin pressure due to destocking and site disruptions. New CEO Umang Vohra focuses on embedding the company into global new drug value chains.
Cohance Lifesciences reported audited FY26 consolidated revenue of ₹2,268.55 Crore. The board also revised authorized personnel for determining materiality effective May 12, 2026.
Cohance Lifesciences Ltd has scheduled a Board Meeting on May 12, 2026, to approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The company's trading window remains closed until May 14, 2026.
Cohance Lifesciences Limited clarified that there is no undisclosed information or event causing the recent share price movement. The company confirmed it remains compliant with SEBI disclosure regulations, having previously intimated the outcome of its April 27, 2026, board meeting.
Cohance Lifesciences Limited has appointed Mr. Umang Vohra as Chairman effective May 1, 2026. This follows the resignation of Mr. Vivek Sharma as Executive Chairman on April 30, 2026, due to personal reasons. Mr. Vohra brings over 30 years of experience, including leadership roles at Cipla and Dr. Reddy's.
Cohance Lifesciences Limited has appointed Mr. Umang Vohra as Chairman and Group CEO. Mr. Vohra brings over 30 years of experience, including leadership roles at Cipla, Dr. Reddy's Laboratories, and PepsiCo India.
Cohance Lifesciences appointed Umang Vohra as Executive Chairman (effective May 1, 2026) and Group CEO (effective May 20, 2026). He succeeds Vivek Sharma, who is stepping down for personal reasons but will remain as an advisor for nine months to ensure a smooth transition. Mr. Vohra previously served as MD and CEO of Cipla.
Cohance Lifesciences approved the appointment of Mr. Umang Vohra as Chairman and Group CEO, succeeding Mr. Vivek Sharma who resigned effective April 30, 2026. The Board also approved the 'Cohance Lifesciences Limited – Employee Stock Option Plan, 2026' covering 2.59 crore options. These leadership transitions and incentive plans are subject to shareholder approval via postal ballot.
Cohance Lifesciences Limited clarified that recent increases in share trading volume are purely market-driven. The company confirmed there is no undisclosed price-sensitive information or pending announcements that could impact trading behaviour. All regulatory disclosures under SEBI Listing Regulations remain up to date.
Cohance Lifesciences Limited clarified that the recent increase in share trading volume is purely market-driven and attributable to prevailing conditions. The company confirmed there is no pending undisclosed price-sensitive information. All regulatory disclosures under SEBI Listing Regulations are up to date, ensuring transparency for investors regarding the scrip's behavior.